TY - JOUR
T1 - Baseline characteristics of European and non-European adult patients with attention deficit hyperactivity disorder participating in a placebo-controlled, randomized treatment study with atomoxetine
AU - Upadhyaya, Himanshu
AU - Adler, Lenard A.
AU - Casas, Miguel
AU - Kutzelnigg, Alexandra
AU - Williams, David
AU - Tanaka, Yoko
AU - Arsenault, Jody
AU - Escobar, Rodrigo
AU - Allen, Albert J.
PY - 2013/5/6
Y1 - 2013/5/6
N2 - Background: Attention deficit/hyperactivity disorder (ADHD) often presents as an impairing lifelong condition in adults; yet it is currently underdiagnosed and undertreated in many European countries. This analysis examines the characteristics of adult patients with ADHD in a European (EUR) and non-European (NE) patient population.Methods: Baseline data from the open-label treatment period of a randomized trial of atomoxetine in adult patients with ADHD (N=2017; EUR, n=1217; NE, n=800) were examined. All patients who were enrolled were included in the baseline analyses.Results: The demographics for patients in the EUR and NE groups were comparable. Patients in the EUR group had a somewhat lower percentage of prior exposure to psychostimulants compared with the NE group (32.7% vs. 38.9%, p=.0049). Scores on the Conners' Adult ADHD Rating Scale-Investigator Rated: Screening Version with adult ADHD prompts (18-item total, inattentive and hyperactive/impulsive subscales, and index) were comparable. The adult ADHD Quality of Life-Life Outlook and Life Productivity domain scores were significantly different between groups (p≤.0004). The EuroQol-5 Dimension United Kingdom and United States population-based index scores and Health State score were comparable between groups.Conclusions: Adults with ADHD in Europe present similar demographics and baseline characteristics to those outside Europe and hence, study results outside Europe may be generalizable to patients in Europe.Trial registration: Clinicaltrials.gov, NCT00700427. © 2013 Upadhyaya et al.; licensee BioMed Central Ltd.
AB - Background: Attention deficit/hyperactivity disorder (ADHD) often presents as an impairing lifelong condition in adults; yet it is currently underdiagnosed and undertreated in many European countries. This analysis examines the characteristics of adult patients with ADHD in a European (EUR) and non-European (NE) patient population.Methods: Baseline data from the open-label treatment period of a randomized trial of atomoxetine in adult patients with ADHD (N=2017; EUR, n=1217; NE, n=800) were examined. All patients who were enrolled were included in the baseline analyses.Results: The demographics for patients in the EUR and NE groups were comparable. Patients in the EUR group had a somewhat lower percentage of prior exposure to psychostimulants compared with the NE group (32.7% vs. 38.9%, p=.0049). Scores on the Conners' Adult ADHD Rating Scale-Investigator Rated: Screening Version with adult ADHD prompts (18-item total, inattentive and hyperactive/impulsive subscales, and index) were comparable. The adult ADHD Quality of Life-Life Outlook and Life Productivity domain scores were significantly different between groups (p≤.0004). The EuroQol-5 Dimension United Kingdom and United States population-based index scores and Health State score were comparable between groups.Conclusions: Adults with ADHD in Europe present similar demographics and baseline characteristics to those outside Europe and hence, study results outside Europe may be generalizable to patients in Europe.Trial registration: Clinicaltrials.gov, NCT00700427. © 2013 Upadhyaya et al.; licensee BioMed Central Ltd.
KW - Adult
KW - Atomoxetine
KW - Attention deficit/hyperactivity disorder
KW - European
U2 - 10.1186/1753-2000-7-14
DO - 10.1186/1753-2000-7-14
M3 - Article
SN - 1753-2000
VL - 7
JO - Child and Adolescent Psychiatry and Mental Health
JF - Child and Adolescent Psychiatry and Mental Health
IS - 1
M1 - 14
ER -